In this regard, the one therapy that has been approved for use in children with severe asthma is the recombinant DNA-derived humanized monoclonal antibody against IgE (omalizumab), which works by reducing the quantity of cell-bound IgE, downregulation of high-affinity IgE receptors FcεRI on MCs, basophils, and DCs, and prevention of mediator release from effector cells (109, 110). The gene discussed is IGHE; the disease is asthma.